Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PHRENILIN vs BUCET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
PHRENILIN is a combination of butalbital, acetaminophen, and caffeine. Butalbital is a barbiturate that enhances GABA-A receptor activity, producing sedation. Acetaminophen inhibits cyclooxygenase (COX) in the CNS, reducing prostaglandin synthesis. Caffeine is a nonselective adenosine receptor antagonist, promoting vasoconstriction and enhancing analgesic effects.
Bucet is a combination of bucetin and acetaminophen. Bucetin is a para-aminophenol derivative with analgesic and antipyretic effects, possibly through inhibition of cyclooxygenase in the central nervous system. Acetaminophen inhibits COX enzymes in the brain, reducing prostaglandin synthesis and fever.
Tension headache
Management of mild to moderate pain,Reduction of fever
For tension headache: 1-2 capsules (each containing butalbital 50 mg, acetaminophen 300 mg, and caffeine 40 mg) orally every 4 hours as needed, not exceeding 6 capsules per day.
Oral: 25-50 mg every 4-6 hours as needed for pain; maximum 200 mg/day.
Butalbital: terminal half-life ~35 hours (range 20-50 h); acetaminophen: ~2-3 hours (prolonged in hepatic impairment); caffeine: ~3-6 hours.
2-4 hours (terminal); prolonged in renal impairment
Butalbital is extensively metabolized by hepatic CYP450 enzymes (especially CYP2C9) and excreted in urine. Acetaminophen is primarily conjugated in the liver via glucuronidation and sulfation, with minor CYP2E1-mediated metabolism to a toxic metabolite (NAPQI). Caffeine is metabolized predominantly by CYP1A2.
Bucetin: Hepatic metabolism via hydroxylation and glucuronidation. Acetaminophen: Hepatic metabolism via glucuronidation, sulfation, and CYP2E1-mediated oxidation to NAPQI.
PHRENILIN (butalbital/acetaminophen/caffeine): Renal excretion of metabolites; butalbital ~60-70% unchanged in urine, acetaminophen ~2-4% unchanged with majority as glucuronide and sulfate conjugates, caffeine metabolites primarily renal.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
Butalbital: ~45% bound to plasma proteins; acetaminophen: 10-25% bound; caffeine: ~35% bound.
~85% bound to albumin
Butalbital: Vd ~0.8 L/kg; acetaminophen: Vd ~0.9 L/kg; caffeine: Vd ~0.6 L/kg. Overall Vd for combination not established; butalbital widely distributed.
0.3-0.5 L/kg; distributes primarily into extracellular fluid
Oral: butalbital ~90% (complete absorption); acetaminophen ~85-90%; caffeine ~100%.
Oral: 75-90%
GFR 30-50 m L/min: Use with caution, maximum 4 capsules per day. GFR <30 m L/min: Avoid use due to accumulation of acetaminophen metabolites and butalbital. Not recommended in dialysis.
GFR 10-50 m L/min: 50% dose reduction; GFR <10 m L/min: avoid use.
Child-Pugh A: Use with caution, maximum 4 capsules per day. Child-Pugh B or C: Contraindicated due to impaired metabolism of butalbital and hepatotoxicity risk from acetaminophen.
Child-Pugh A: no adjustment; Child-Pugh B: 50% dose reduction; Child-Pugh C: avoid use.
Not recommended in children under 12 years of age due to butalbital and caffeine content. For adolescents 12-17 years: 1 capsule orally every 4 hours as needed, not exceeding 3 capsules per day.
Children 6-12 years: 5 mg/kg/dose every 6 hours as needed; maximum 20 mg/kg/day.
Initiate at 1 capsule orally every 4 hours as needed, not exceeding 4 capsules per day. Monitor for sedation, cognitive impairment, and falls. Avoid in patients with severe hepatic or renal impairment.
Start at lowest effective dose (12.5 mg every 6 hours); maximum 150 mg/day due to increased fall risk and renal impairment.
Barbiturates (butalbital) are habit-forming and may produce drug dependence. Withdrawal symptoms (e.g., anxiety, insomnia, seizures) can occur if abruptly discontinued. Use with caution in patients with a history of substance abuse.
No FDA black box warnings for bucet. Acetaminophen component: Risk of severe liver injury at high doses or with alcohol use.
Hepatotoxicity (acetaminophen) with overdose or chronic use; risk of dependence and withdrawal with butalbital; potential for caffeine-related effects (insomnia, palpitations); caution in patients with liver disease, renal impairment, or history of substance abuse.
Hepatotoxicity risk with acetaminophen overdose,Avoid alcohol use,Hypersensitivity reactions,Skin reactions (Stevens-Johnson syndrome)
Hypersensitivity to any component; porphyria (butalbital); severe hepatic impairment (acetaminophen); concurrent use of MAOIs or other CNS depressants may potentiate effects.
Severe hepatic impairment,Hypersensitivity to bucetin or acetaminophen
Avoid or limit caffeine-containing foods and beverages (coffee, tea, cola, chocolate) due to additive caffeine content. Alcohol should be strictly avoided due to enhanced CNS depression and hepatotoxicity risk. Grapefruit juice may affect caffeine metabolism; monitor for increased caffeine effects.
No known food interactions. Avoid alcohol as it may increase risk of side effects like dizziness.
Butalbital: First trimester: Risk of major malformations (OR 1.4-2.0) including oral clefts; increased risk with prolonged use. Second and third trimesters: Avoid chronic use due to risk of neonatal withdrawal syndrome and hemorrhagic disease of newborn due to vitamin K deficiency. Acetaminophen: Considered low risk; no consistent evidence of teratogenicity. Caffeine: No increased risk of major malformations at moderate intake (<200 mg/day); high doses may be associated with growth restriction.
FDA Pregnancy Category D. First trimester: Increased risk of cardiac malformations and neural tube defects. Second and third trimesters: Risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment.
Butalbital: Excreted into breast milk; M/P ratio unknown. Monitor infant for sedation, poor feeding, or withdrawal symptoms. Acetaminophen: Excreted in low amounts; M/P ratio approximately 1.0; considered compatible. Caffeine: Excreted in milk; M/P ratio 0.5-0.8; moderate intake likely safe; excessive use may cause irritability in infant.
Contraindicated. Excreted in human milk; M/P ratio not established. Potential for serious adverse effects in nursing infant.
No specific dose adjustments for butalbital or acetaminophen based on pregnancy pharmacokinetics. However, avoid prolonged use or high doses. For caffeine, limit to <200 mg/day. Use lowest effective dose for shortest duration. Monitor for signs of butalbital accumulation in pregnancy due to increased volume of distribution; no formal recommendation for dose reduction.
Avoid use during pregnancy. If unavoidable, reduce dose by 50% due to increased clearance and altered protein binding.
Phrenilin is a combination of butalbital, acetaminophen, and caffeine. Butalbital is a barbiturate; use with caution in patients with history of substance abuse or depression. Acetaminophen hepatotoxicity risk increases with doses >4g/day or in alcohol use disorder. Caffeine may exacerbate anxiety, insomnia, or tachyarrhythmias. Monitor for sedation and respiratory depression when used with other CNS depressants. Avoid abrupt discontinuation to prevent withdrawal symptoms.
Bucet (bupivacaine hydrochloride and epinephrine) is used for local anesthesia. Epinephrine prolongs anesthetic effect and reduces systemic absorption. Avoid in patients with severe hypertension, hyperthyroidism, or concurrent MAO inhibitors. Monitor for CNS and cardiac toxicity, especially with high doses. Epinephrine concentration is 1:200,000; check for allergy to sulfites (antioxidant).
Take only as prescribed; do not exceed recommended dose to avoid liver damage or addiction.,Avoid alcohol while taking this medication due to increased risk of liver toxicity and sedation.,Do not drive or operate heavy machinery until you know how this medication affects you.,If you have a history of substance abuse, inform your doctor before taking this medication.,Common side effects include drowsiness, dizziness, and nausea. Report severe allergic reactions or signs of liver damage (yellowing skin/eyes, dark urine, abdominal pain).,Do not stop taking suddenly without consulting your doctor, as withdrawal symptoms may occur.,Keep out of reach of children; acetaminophen overdose can be fatal.
Do not drive or operate machinery until numbness subsides.,Avoid touching or scratching the numb area to prevent injury.,Report any signs of allergic reaction (rash, swelling, difficulty breathing) or intravenous injection symptoms (rapid heart rate, anxiety, headache).,The numbness will wear off over several hours depending on the dose and site.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PHRENILIN vs BUCET, answered by our medical review team.
PHRENILIN is a Barbiturate/Analgesic Combination that works by PHRENILIN is a combination of butalbital, acetaminophen, and caffeine. Butalbital is a barbiturate that enhances GABA-A receptor activity, producing sedation. Acetaminophen inhibits cyclooxygenase (COX) in the CNS, reducing prostaglandin synthesis. Caffeine is a nonselective adenosine receptor antagonist, promoting vasoconstriction and enhancing analgesic effects.. BUCET is a Barbiturate Combination Analgesic that works by Bucet is a combination of bucetin and acetaminophen. Bucetin is a para-aminophenol derivative with analgesic and antipyretic effects, possibly through inhibition of cyclooxygenase in the central nervous system. Acetaminophen inhibits COX enzymes in the brain, reducing prostaglandin synthesis and fever.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PHRENILIN and BUCET depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PHRENILIN is: For tension headache: 1-2 capsules (each containing butalbital 50 mg, acetaminophen 300 mg, and caffeine 40 mg) orally every 4 hours as needed, not exceeding 6 capsules per day.. The standard adult dose of BUCET is: Oral: 25-50 mg every 4-6 hours as needed for pain; maximum 200 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PHRENILIN and BUCET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PHRENILIN is classified as Category C. Butalbital: First trimester: Risk of major malformations (OR 1.4-2.0) including oral clefts; increased risk with prolonged use. Second and third trimesters: Avoid chronic use due t. BUCET is classified as Category C. FDA Pregnancy Category D. First trimester: Increased risk of cardiac malformations and neural tube defects. Second and third trimesters: Risk of premature closure of ductus arterio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.